In 2005, CVBT is well along the pathway of commercializing FGF-1141 for use in the heart. In 2003, CVBT started U.S. FDA-authorized clinical trials that are now ongoing at six US medical centers.

The first results from this trial, which were highly promising, were reported in the Cincinnati Enquirer, and on ABC World News Tonight on May 12, 2004. In addition, medical researchers from the University of Cincinnati Hospital were invited to give a Plenary Session presentation on their clinical results at the 2004 American Heart Association’s meeting in New Orleans. The current studies examine different doses of FGF-1141 and the drug’s effect to stimulate new blood vessel growth in the hearts of no-option patients.

< Back to Heart                                           Go to Bypass Treatment >

<< Return to Treatment Applications

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.